ERBB2 and breast carcinoma: Watanabe and colleagues evaluated TILs in HR+/HER2- primary breast cancers before and after NAC, and concluded that low TILs following NAC, but not at baseline, were associated with a significantly better recurrence free survival (RFS) (49).